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Yes,	warfarin	is	effective	in	the	secondary	
prevention	of	venous	thromboembolic	
events	(vTes)	for	patients	positive	for	
lupus	anticoagulant	or	anticardiolipin	
antibody	(also	known	as	antiphospholipid	
antibodies	[apl])	(strength	of	
recommendation	[sor]:	B,	single	cohort	
study,	extrapolation	from	other	rCTs).	
patients	should	be	treated	for	at	least	a	
year	(sor:	C,	consensus	statement),	and	
possibly	indefinitely,	with	warfarin	(sor:	
B,	small	clinical	trials	and	cohort	studies).	
Moderate-intensity	therapy	(international	
normalized	ratio	[iNr]	range,	2.0–3.0)	
appears	to	be	the	best	balance	between	
risks	and	benefits	(sor:	B,	based	on	
meta-analysis	of	2	small	randomized	
control	trials).	
	 little	evidence	exists	regarding	primary	
prevention	for	patients	with	an	incidental	
finding	of	either	apl.	For	these	individuals,	
the	risks	of	warfarin	may	outweigh	any	
benefits.	Many	experts	recommend	
primary	prevention	with	aspirin	for	those	
individuals	who	are	apl	positive	and	
who	do	not	have	contraindications	to	
aspirin	or	another	compelling	reason	for	
warfarin	use	(malignancy,	family	history,	
or	accompanying	hypercoagulable	state)	
(sor:	C,	expert	opinion).
Clinical commentary
Consider this syndrome when  
a younger patient has had an idiopathic 
thromboembolism episode
antiphospholipid	antibodies	have	a	
prevalence	rate	of	1%	to	5%	in	the	
general	population,	and	12%	to	34%	
among	patients	with	systemic	lupus	
erythematosus.1	The	prevalence	of	
antiphospholipid	antibodies	increases	
with	age,	especially	among	elderly	
patients	with	coexistent	chronic	illness.	
	 patients	with	antiphospholipid	
antibodies	are	not	always	symptomatic.	
Common	manifestations	may	include	
arterial	and	venous	thromboembolic	events,	
frequent	miscarriage,	thrombocytopenia,	
hemolytic	anemia,	and	livedo	reticularis.2
	 Family	physicians	should	consider	
this	syndrome	when	a	patient	≤50	years	
old	has	had	an	episode	of	idiopathic	
thromboembolism,	or	an	unexplained	
elevated	activated	partial-thromboplastin	
time,	or	a	history	of	miscarriage.	a	previous	
study3	reported	that	presence	of	lupus	
anticoagulant	is	associated	with	increased	
risk	of	recurrent	thromboembolic	events.
Therefore,	it’s	reasonable	to	continue	
anticoagulation	with	warfarin	indefinitely	for	
these	patients,	after	their	first	episode	of	a	
thromboembolic	event.
Vincent lo, MD
san	Joaquin	General	Hospital,	French	Camp,	Calif
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Lupus anticoagulant and anticardio-
lipin antibodies are known to increase 
risk of both arterial and venous throm-
boembolic events. 
One study prospectively followed 
patients ≥15 years old recruited from 16 
hospitals in Sweden, who had their first 
or second episode of a VTE. Patients 
with malignancy or a known congenital 
deficiency of an inhibitor of coagula-
tion were excluded. These patients were 
followed for 4 years. Each received 
at least 6 months of warfarin therapy 
(INR=2.0–2.85) after initial diagnosis 
of a VTE. 
After treatment, the 4-year re-
currence rate for VTEs was 29% for 
patients with aPL (20/68) vs 14% for 
patients without (47/344) (relative risk 
[RR]=2.1; 95% confidence interval [CI], 
1.3–3.3). The risk of death for those 
patients with aPL was 15% (10/68) vs 
6% for those without (20/324) (RR=1.8; 
95% CI, 0.9–3.6). 
In the same study, those with an 
aPL and a second clot were random-
ized to a second 6 months of therapy 
vs indefinite therapy (INR=2.0–2.85). 
After 4 years, their risk of another re-
currence was 20% (3/15) with 6 months 
of therapy vs 5% (1/19) with indefinite 
therapy. This underpowered study did 
not show a statistical difference under 
intention-to-treat analysis; however, the 
single failure in the treatment group 
had stopped the warfarin prior to the 
event.4
Moderate intensity therapy  
does the job
Two recent randomized controlled tri-
als have shown that moderate-inten-
sity warfarin therapy (INR=2.0–3.0) 
is equally efficacious to high-intensity 
therapy (INR=3.0–4.0).5,6 In these small 
studies, those with aPL were random-
ized to moderate-intensity vs high- 
intensity therapy and followed for ap-
proximately 3 years. A meta-analy-
sis of these studies (done in conjunc-
tion with the second study) remained 
insufficiently powered to show any 
significant differences between high- 
and moderate-intensity therapy, but 
there was a trend towards increased 
thrombosis and bleeding events in the 
high-intensity groups.6 Of note, the 
relative risk for developing a VTE was 
lower in these studies than in those with 
time-limited treatment, suggesting that 
indefinite treatment may be indicated. 
Warfarin probably isn’t best  
for primary prevention
Wahl et al7 constructed a decision 
analysis of antithrombotic therapy for 
patients with systemic lupus erythema-
tosus with and without aPL. They com-
pared observation alone with aspirin 
and with warfarin for the primary pre-
vention of VTE. Using a decision analy-
sis based on the best available efficacy 
rates, they recommended that the ben-
efits of prophylactic aspirin outweigh 
the risks. However, due to high com-
plication rates, warfarin’s benefits are 
outweighed by the risks. This analysis 
has not been validated in an actual pa-
tient population and remains theoreti-
cal in nature, but is the best available 
evidence regarding primary prevention 
of VTE for patients with aPL.
Recommendations from others
Guidelines from the American College 
of Chest Physicians recommend at least 
12 months of treatment with warfarin 
and suggest indefinite treatment for pa-
tients with a VTE and antiphospholipid 
antibodies. The guidelines also suggest a 
target INR of 3.0 (range, 2.5–3.5) for pa-
tients with recurrent VTEs or additional 
risk factors, and a therapeutic INR of 2.5 
(range, 2.0–3.0) for patients with a VTE 
and lupus anticoagulant but no addition-
al risk factors.8
The Thrombosis Interest Group of 
Canada also recommends considering in-
definite treatment for those with a VTE 
and a positive test for any of the antiphos-
pholipid antibodies.9 n
American College 
of Chest Physicians 
advisory:  
12 months of  
warfarin, and  
indefinite therapy 
if a VTE patient has 
antiphospholipid 
antibodies
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